Skip to main content

Anika Therapeutics Aktie - Fundamentalanalyse - Dividendenrendite KGV

Anika Therapeutics (ISIN: US0352551081, WKN: 889120) Kursdatum: 17.11.2017 Kurs: 53,390 USD
Beschreibung Daten
Symbol ANIK
Marktkapitalisierung 807.043.264,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet www.anikatherapeutics.com
Letztes Bilanz Update 24.02.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 17.11.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
82,46 33,91 0,00% 13,53 92,73 24,83 7,81 3,62

Firmenbeschreibung

18. Quarterly Financial Data (Unaudited)   Year 2015   Quarter ended December 31,   Quarter ended September 30,   Quarter ended June 30,   Quarter ended March 31, Product revenue   $ 25,607     $ 23,676     $ 22,898     $ 15,515   Total revenue     30,894       23,681       22,904       15,520   Cost of product revenue     6,290       5,176       5,274       4,313   Gross profit on product revenue     19,317       18,500       17,624       11,202   Net income   $ 11,042     $ 8,380     $ 7,820     $ 3,516   Per common share information:                                 Basic net income per share   $ 0.74     $ 0.56     $ 0.52     $ 0.24   Basic common shares outstanding     14,965       14,967       14,961       14,905   Diluted net income per share   $ 0.72     $ 0.55     $ 0.51     $ 0.23   Diluted common shares outstanding     15,353       15,316       15,336       15,330     Year 2014   Quarter ended December 31,   Quarter ended September 30,   Quarter ended June 30,   Quarter ended March 31, Product revenue   $ 17,880     $ 21,975     $ 21,267     $ 14,352   Total revenue     23,255       22,055       26,275       34,010   Cost of product revenue     5,511       5,725       5,333       4,361   Gross profit on product revenue     12,369       16,250       15,934       9,991   Net income   $ 7,816     $ 6,171     $ 9,302     $ 15,030   Per common share information:                                 Basic net income per share   $ 0.53     $ 0.42     $ 0.63     $ 1.04   Basic common shares outstanding     14,801       14,759       14,688       14,461   Diluted net income per share   $ 0.51     $ 0.40     $ 0.60     $ 0.97   Diluted common shares outstanding     15,278       15,435       15,493       15,499  

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.anikatherapeutics.com